Abstract: The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

Abstract: The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

Abstract: The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

Abstract: Disclosed herein are assays and methods for diagnosis and prognosis of lung cancer using expression analysis of one or more genes from a biological sample comprising nasal epithelial cells. The assays and methods of the invention provide non-invasive means of accurately detecting the presence or absence of lung cancer relative to, for example, more invasive techniques, such as bronchoscopy. Similarly, in certain aspects, the assays and methods disclosed herein provide non-invasive means of accurately identifying the smoking history of a subject.

Abstract: The invention described herein relates to methods of treating emphysema and COPD with a GHK tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein.

Abstract: The invention described herein relates to methods of treating emphysema and COPD with a GHK tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein.

Abstract: The invention described herein relates to methods of treating emphysema and COPD with a GHK tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein.

Abstract: The invention described herein relates to methods of treating emphysema and COPD with a GHK tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein.

Abstract: A method of predicting an efficacy of an oncolytic virus treatment for a tumor comprises calculating a single-gene predictor score for each of a plurality of genes; calculating a predictor score from the sum of the single-gene predictor scores for the plurality of genes; and predicting, if the predictor score is greater than a predictor score threshold, that the treatment would have efficacy, and if the predictor score is less than a predictor score threshold, that the treatment would lack efficacy. Also, methods of predicting an efficacy of a treatment for a tumor comprise identifying the type and subtype of the tumor, wherein the efficacy of the treatment for the type and subtype of the tumor is known.